By Denny Jacob
Omnicell shares rose 5.8% after the company updated its guidance following a temporary reduction in tariffs on China.
Shares were trading around $28.93. The stock is down around 35% on the year.
The healthcare technology company, which automates medication management for hospitals and pharmacies, said it now expects adjusted earnings per-share in the range of 24 cents and 34 cents in the second quarter. It previously forecast adjusted earnings per-share between 19 cents and 32 cents.
For 2025, adjusted earnings are forecast to come in between $1.30 a share and $1.65 a share. It previously forecast adjusted earnings per-share between $1 and $1.65.
Omnicell also disclosed its board approved a new $75 million stock repurchase program, adding to the buyback program approved in 2016 allowing for the repurchase of up to $50 million of the company's common stock.
Chief Executive Randall Lipps said the Trump administration's recent reduction in tariffs on China compelled the company to update its guidance to reflect "the expected diminished impact on our supply chain and anticipated improved profitability."
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 22, 2025 11:17 ET (15:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.